Clinical Trial Update: TMC435-TiDP16-C123 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and the Antiretroviral Agents Efavirenz and Raltegravir [Phase 1]

View source ↗

Summary

A Phase 1 study in healthy volunteers assessing the pharmacokinetic interaction between the anti-HCV candidate TMC435 and antiretroviral agents efavirenz and ra…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Isentress (Raltegravir)
• Sustiva (efavirenz)
• TMC435

Snippet

Sponsor: Tibotec Pharmaceuticals, Ireland | Conditions: Hepatitis C Virus | Phase 1 | Status: COMPLETED